On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025
Second Antibody Drug Conjugate Is Next Milestone
Executive Summary
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.
You may also be interested in...
AstraZeneca’s Triple Regulatory Wins For Enhertu, Tezspire And Ultomiris Herald Sales Boost
The major has won US priority review for a commercially crucial label expansion of its breast cancer drug Enhertu while Tezspire and Ultomiris attracted positive CHMP opinions across the Atlantic.
Beam Therapeutics’ Base-Edited CAR-T Placed On Hold
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.
Barron Signs Off With Notes On GSK Culture Change, Tease On RSV Vaccine Results
Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.